Skip to content
Brand AI

Exelixis

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    External criticism of Cabometyx pricing

    The Institute for Clinical and Economic Review included Cabometyx in a review of high-expenditure medicines whose net price increases were considered insufficiently supported by new clinical evidence. The criticism concerned pricing and payer burden rather than an allegation of product safety misconduct.